Data Article

Single and joint impact of type 2 diabetes and of congestive heart failure on albuminuria: Data from subgroup analysis and data on moderate albuminuria

Christoph H. Saely a,b,c,1, Maximilian Maechler a,b,c,1, Alexander Vonbank a,b,c, Lukas Sprenger a,b,c, Arthur Mader a,b,c, Barbara Larcher a,b,c, Daniela Zanolin-Purin a,b, Andreas Leiherer a, Axel Muendlein a, Heinz Drexel a, b, c, d, *

a Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, Feldkirch AT-6800, Austria
b Private University in the Principality of Liechtenstein, Dorfstrasse 24, Triesen FL-9495, Liechtenstein
c Department of Medicine I, Academic Teaching Hospital Feldkirch, Carinagasse 47, Feldkirch AT-6800, Austria
d Drexel University College of Medicine, 2900 W Queen Ln, Philadelphia, PA 19129, United States

A R T I C L E   I N F O

Article history:
Received 16 December 2021
Revised 5 January 2022
Accepted 6 January 2022
Available online 10 January 2022

Keywords:
Albumin-creatinine ratio
Heart failure
Diabetes mellitus
Gender differences
Moderate albuminuria

A B S T R A C T

We investigated 180 consecutive patients with congestive heart failure (CHF), of whom 83 had type 2 diabetes (T2DM) and 97 did not have diabetes as well as 223 controls without CHF, of whom 39 had T2DM and 184 did not have diabetes. Data was recorded by standardized interviews and by standardized examination protocols at our institution and were extracted from medical records. Here, we analyzed data on gender differences. Further, we examined the effect of CHF and T2DM on moderate albuminuria, i.e. on an albumin-creatinine ratio (ACR) of 30–300 mg/g. Table 1 shows baseline characteristics of our patients stratified by gender. Table 2 gives ACRs and prevalence rates of albuminuria separately for men and women.

DOI of original article: 10.1016/j.jdiacomp.2021.108046
* Corresponding author at: Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, Feldkirch AT-6800, Austria.
E-mail addresses: heinz.drexel@vivit.at, vivit@lkhf.at (H. Drexel).
1 These author contributed equally to this work.

https://doi.org/10.1016/j.dib.2022.107817
2352-3409/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
In logistic regression analyses adjusting for age, sex, body mass index, LDL cholesterol, history of smoking, history of hypertension, use of statins, ACE inhibitors/angiotensin II receptor blockers, aldosterone antagonists and other antihypertensive medication CHF and T2DM predicted the prevalence of albuminuria in a mutually independent manner in men (OR 4.93 [95% CI 1.76–13.85]; \( p = 0.002 \) and OR 2.38 [1.11–5.11]; \( p = 0.027 \), respectively), as well as in women (OR 5.66 [95% CI 1.76–18.20]; \( p = 0.004 \) and OR 3.53 [1.38–9.08]; \( p = 0.009 \), respectively). There was no significant interaction between gender and CHF or T2DM regarding the presence of albuminuria (\( p = 0.933 \) and 0.533, respectively), indicating that the association of CHF and T2DM with albuminuria did not differ significantly between men and women.

In multivariate analysis of covariance, CHF and T2DM proved to be independent predictors of ACR in women after adjustment for age, sex, body mass index, LDL cholesterol, history of smoking, history of hypertension, use of statins, ACE inhibitors/angiotensin II receptor blockers, aldosterone antagonists and other antihypertensive medication (\( F = 5.38; \ p = 0.022 \) and \( F = 4.95; \ p = 0.028 \), respectively); for men the corresponding F-values were 2.70; \( p = 0.102 \) and 3.12; \( p = 0.079 \), respectively. There was no significant interaction between gender and CHF or T2DM regarding ACR (\( p = 0.464 \) and 0.202, respectively), indicating that the association of CHF and T2DM with the ACR did not differ significantly between men and women.

Regarding moderate albuminuria, both CHF and T2DM predicted moderate albuminuria adjusted in a mutually independent manner after the adjustments described above, with ORs of 4.75 [95% CI 2.16–10.45]; \( p< 0.001 \) and OR 2.08 [1.13–3.83]; \( p=0.018 \), respectively.

The data set presented here could be reused with similar patient cohorts for pooled analysis.

© 2022 The Authors. Published by Elsevier Inc.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

---

**Specifications Table**

| Subject | Cardiology and Cardiovascular Medicine |
|---------|----------------------------------------|
| Specific subject area | Associations of congestive heart failure and type 2 diabetes with albuminuria, taking into account potential gender differences. |
| Type of data | Table |
| How the data were acquired | Consecutive patients admitted for congestive heart failure (CHF) to a tertiary care center were enrolled; as controls we used patients without signs and symptoms of congestive heart failure in whom coronary artery disease was ruled out angiographically. Information on conventional cardiovascular risk factors were obtained by standardized interviews. Biochemical measurements were obtained from fasting venous blood or urine samples, taken within one day of enrolment. Systolic and diastolic blood pressure was measured by the Riva-Rocci method under resting conditions in a sitting position at the day of inclusion and at least five hours after hospitalization. Height and weight were recorded at the day of admission, and body mass index was calculated as body weight (kg) / height (m)². Left ventricular ejection fraction was obtained by transthoracic echocardiography. Data was organized in an encrypted dataset using IBM SPSS Statistics 24.0.0.0 for Windows (SPSS, Inc., USA). |

(continued on next page)
Data format | Analyzed Filtered Raw
---|---|---
Description of data collection | Diagnosis of congestive heart failure was made according to the 2016 European Society of Cardiology (ESC) definition [2]. As controls we used 223 consecutive patients who had no signs or symptoms of CHF and in whom significant coronary artery disease (CAD) was ruled out angiographically. Significant CAD was defined as at least one lesion with a stenosis of 50% or more on coronary angiogram, as we already described before [3]. All patients were routinely screened for diabetes using HbA1c and fasting plasma glucose if a diagnosis of diabetes had not been already established previously. The diagnosis of type 2 diabetes (T2DM) was made according to 2020 ADA criteria [4]. Patients with acute coronary syndrome (ACS) and/or patients with type 1 diabetes (C-peptide negative) were not enrolled.

Data source location | Institution: Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) and Department of Medicine I, Academic Teaching Hospital Feldkirch | City/Town/Region: Feldkirch, Vorarlberg | Country: Austria

Data accessibility | Repository name: Mendeley Data | Data identification number: 10.17632/7cp325hk29.1 | Direct URL to data: https://data.mendeley.com/datasets/7cp325hk29/1

data was fully anonymised and therefore no access control is needed

Related research article | Saely CH, Maechler M, Vonbank A, Sprenger L, Mader A, Larcher B, Zanolin-Purin D, Leherer A, Muendlein A, Drexel H. Single and joint impact of type 2 diabetes and of congestive heart failure on albuminuria. J Diabetes Complications. 2021 Dec;35(12):108046. doi: 10.1016/j.jdiacomp.2021.108046. Epub 2021 Sep 12. PMID: 34598838.

Value of the Data

- T2DM and congestive heart failure are highly prevalent and often are combined in one patient. Albuminuria predicts cardiovascular morbidity and mortality in T2DM [5,6], as well as in CHF [7,8]; the prevalence of albuminuria is increased both in T2DM [9] and CHF [5], but the single and joint effects of T2DM on albuminuria in gender specific analyses had not yet been addressed.
- The data benefit researchers as well as health care professionals in the fields of diabetology, cardiology, nephrology and general internal medicine.
- Our data should stimulate the development of study protocols to gain further insight into the interplay between albuminuria, congestive heart failure and T2DM, including prospective investigations and interventional studies.

1. Data Description

- Table 1 Shows the baseline characteristics in men and women of our study population with regard to the presence of both CHF and T2DM [1]. The values listed represent the mean and the standard deviation with a confidence interval of 95% unless denoted otherwise. Statistical significance was defined as two-tailed p-value of 0.05.
- Table 2 Shows ACRs and the prevalence of albuminuria in men and women with regard to the presence of both CHF and T2DM. The values in the table are listed in the same way as described for Table 1.
- Dataset: Features the data of our study population including the presence of CHF and T2DM, gender, ACR and prevalence of albuminuria. The data are pseudonymized as each participant was assigned to consecutive numbers (“ID”) on the basis of date of inclusion. The variables “Diabetes_mellitus_type_2” and “congestive_heart_failure” distinguish if subjects are
Table 1
Baseline characteristics of study population, mean ± SD (95% CI), statistical significance was defined as two-tailed p value of 0.05.

|                      | CHF - T2DM- n = 184 (45.7%) | CHF - T2DM+ n = 39 (9.7%) | p-value | CHF + T2DM- n = 97 (24.1%) | CHF + T2DM+ n = 83 (20.6%) | p-value |
|----------------------|-----------------------------|---------------------------|---------|---------------------------|---------------------------|---------|
| Age (years)          |                             |                           |         |                           |                           |         |
| Men                  | 57 ± 11 (54.4–58.7)         | 64 ± 11 (59.3–68.7)       | 0.006   | 69 ± 15 (64.9–72.6)       | 72 ± 11 (68.6–75.0)       | 0.364   |
| Women                | 62 ± 10 (60.1–64.3)         | 63 ± 7 (59.8–67.2)        | 0.618   | 78 ± 16 (72.8–83.0)       | 76 ± 13 (71.6–80.8)       | 0.399   |
| BMI (kg/m²)          |                             |                           |         |                           |                           |         |
| Men                  | 28 ± 4 (26.8–28.3)          | 30 ± 3 (28.2–30.9)        | 0.004   | 26 ± 5 (25.1–27.7)        | 30 ± 6 (28.1–31.2)        | 0.001   |
| Women                | 28 ± 5 (26.6–28.7)          | 34 ± 6 (31.0–36.8)        | <0.001  | 27 ± 6 (25.0–28.6)        | 28 ± 9 (24.8–31.0)        | 0.959   |
| History of Smoking (%) |                           |                           |         |                           |                           |         |
| Men                  | 68.7                        | 90.9                      | 0.034   | 69.0                      | 68.6                      | 0.970   |
| Women                | 41.2                        | 29.4                      | 0.364   | 35.9                      | 34.4                      | 0.894   |
| History of hypertension (%) |                     |                           |         |                           |                           |         |
| Men                  | 57.6                        | 81.8                      | 0.034   | 62.6                      | 82.4                      | 0.019   |
| Women                | 55.3                        | 88.2                      | 0.011   | 71.8                      | 87.5                      | 0.107   |
| LDL-C (mg/dl)        |                             |                           |         |                           |                           |         |
| Men                  | 132 ± 35 (125–139)          | 129 ± 37 (112–145)        | 0.778   | 121 ± 54 (107–136)        | 129 ± 68 (109–148)        | 0.516   |
| Women                | 143 ± 38 (135–151)          | 110 ± 38 (90–129)         | 0.004   | 125 ± 43 (110–139)        | 135 ± 53 (114–155)        | 0.359   |
| Use of antihypertensive drugs (%) |                     |                           |         |                           |                           |         |
| Men                  | 65.7                        | 81.8                      | 0.140   | 100.0                     | 100.0                     | 1.000   |
| Women                | 55.3                        | 88.2                      | 0.011   | 97.4                      | 100.0                     | 0.362   |
| Use of ACEi or ARBs (%) |                           |                           |         |                           |                           |         |
| Men                  | 32.3                        | 36.4                      | 0.716   | 73.2                      | 64.0                      | 0.306   |
| Women                | 29.4                        | 41.2                      | 0.340   | 47.4                      | 59.4                      | 0.316   |
| Use of aldosterone antagonists (%) |                     |                           |         |                           |                           |         |
| Men                  | 1.0                         | 0.0                       | 0.636   | 44.6                      | 36.0                      | 0.366   |
| Women                | 2.4                         | 5.9                       | 0.432   | 23.1                      | 9.4                       | 0.125   |
| Prevalence of albuminuria (%) * |                     |                           |         |                           |                           |         |
| Men                  | 9.1                         | 22.7                      | 0.070   | 36.2                      | 56.9                      | 0.031   |
| Women                | 8.2                         | 23.5                      | 0.063   | 41.0                      | 71.9                      | 0.009   |
| Prevalence of moderately increased albuminuria (%) ° |             |                           |         |                           |                           |         |
| Men                  | 7.2                         | 19.0                      | 0.091   | 33.9                      | 47.6                      | 0.171   |
| Women                | 8.2                         | 23.5                      | 0.063   | 36.1                      | 65.4                      | 0.023   |

CHF = congestive heart failure, T2DM = type 2 diabetes mellitus, BMI = body mass index, LDL-C = low-density lipoprotein cholesterol, ACEi = ACE Inhibitor, ARB = Angiotensin receptor blocker.

* defined as ACR ≥ 30 mg/g; defined as ACR 30–300 mg/g.
Table 2

ACR and prevalence of albuminuria in men and women, median [interquartile range], statistical significance was defined as two-tailed p value of 0.05.

|                      | CHF -                              |                     | CHF +                              |                     |
|----------------------|------------------------------------|---------------------|------------------------------------|---------------------|
|                      | T2DM- n = 99 (43.0%)               | T2DM+ n = 22 (9.6%) | p-value                            | T2DM- n = 58 (25.2%)| T2DM+ n = 51 (22.2%)| p-value |
| ACR (mg/g)           |                                    |                     |                                    |                     |                     |         |
| Men                  | 7.8 [4.8–15.1]                     | 13.1 [8.4–29.9]     | **0.003**                          | 20.0 [8.5–73.6]     | 59.0 [16.0–168.0]   | **0.006**|
| Women                | 11.9 [6.6–17.7]                    | 16.7 [6.2–31.5]     | 0.188                              | 25.0 [9.0–82.0]     | 73.5 [16.0–222.8]   | **0.033**|
| Prevalence of albuminuria (%) * |                      |                     |                                    |                     |                     |         |
| Men                  | 9.1                                | 22.7                | 0.070                              | 36.2                | 56.9                | **0.031**|
| Women                | 8.2                                | 23.5                | 0.063                              | 38.2                | 62.7                | **0.009**|

CHF = congestive heart failure, T2DM = type 2 diabetes mellitus, ACR = albumin-creatinine ratio.

* defined as ACR ≥ 30 mg/g.
suffering from T2DM and/or CHF, whereas “0” encodes “no” and “1” stands for “yes”. “Sex” describes the biological sex of subjects, whereas “0” stands for “female” and “1” for “male” patients. The variable “albumin_creatinine_ratio” describes the quantity of albumin-creatinine ratio (ACR) in mg/g. Finally, the variable “moderate_albuminuria” states if subjects suffer from moderate albuminuria, which is defined as an ACR of 30–300 mg/g, and as before “0” stands for “no” and “1” for yes.

• Questionnaire: The questionnaire used for the standardized interview and examination of every subject.

2. Experimental Design, Materials and Methods

We ruled in consecutive patients who were admitted to the LKH Feldkirch, a tertiary care center in Austria, for congestive heart failure. Eligible patients were identified via the hospital record system. As a control group we used consecutive patients who were admitted for coronary angiography with no signs or symptoms of CHF according to the 2016 European Society of Cardiology (ESC) definition [2] and in whom coronary artery disease was ruled out by angiography. Demographics, patient history and relevant medical findings were obtained by a standardized interview and examination. Biochemical measurements were obtained from fasting venous blood or urine samples, taken within one day of inclusion.

The diagnosis of type 2 diabetes (T2DM) was made according to 2020 ADA criteria [4]. Diagnosis of congestive heart failure was made according to the 2016 European Society of Cardiology (ESC) definition [2].

ACR was measured on either cobas c501/c502, c702 or Integra 800 (Roche, Switzerland) using fasting morning urine (ACN 253 or ACN 8253 for albumin by immunoturbidimetry and ACN 691 or ACN 8691 for creatinine by Jaffe reaction). Moderate albuminuria was defined as a range of ACR of 30 mg/g or more and 300 mg/g or less.

NT-proBNP was measured on cobas e601, e602, e801 or Elecsys 2010 (Roche, Switzerland) using corresponding, commercially available, immunological tests. Hba1c-levels were measured on Adams HA-8160 (Arkay, Japan) using High Performance Liquid Chromatography.

Between-group differences were tested for statistical significance using Mann–Whitney–U test for continuous variables and by applying the chi-squared test for categorical variables. Analyses of covariance (ANCOVA) was performed using the general linear model approach, and logistic regression analyses were applied. Results are described as mean median [interquartile range] if not denoted otherwise. Statistical significance was defined as two-tailed p value of 0.05. All statistical analyses were performed with the software package IBM SPSS Statistics 24.0.0.0 for Windows (SPSS, Inc., USA).

Ethics Statements

We hereby state that the research has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki), that the Ethics Committee of the University of Innsbruck approved this study (EK-2-2008/0017) and that all participants gave written informed consent.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
CRediT Author Statement

**Christoph H. Saely:** Conceptualization, Methodology, Validation, Writing – review & editing, Supervision; **Maximilian Maechler:** Validation, Formal analysis, Investigation, Writing – original draft, Visualization; **Alexander Vonbank:** Writing – review & editing; **Lukas Sprenger:** Investigation, Visualization; **Arthur Mader:** Investigation, Visualization; **Barbara Larcher:** Investigation, Visualization; **Daniela Zanolin-Purin:** Investigation, Formal analysis; **Andreas Leiberer:** Writing – review & editing; **Axel Muendlein:** Writing – review & editing; **Heinz Drexel:** Conceptualization, Supervision, Project administration.

Acknowledgments

This work was supported by the Jubiläumsfonds of the Austrian National Bank (Vienna, Austria), Dr. Karl Josef Hier and the Peter Goop Stiftung (Vaduz, Liechtenstein), the Fachhochschule Dornbirn (Dornbirn, Austria), and the Institute for Clinical Chemistry at the Academic Teaching Hospital Feldkirch (Feldkirch, Austria). We would like to thank the above mentioned for providing us with generous research grants.

Supplementary Materials

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.dib.2022.107817.

References

[1] C.H. Saely, M. Maechler, A. Vonbank, L. Sprenger, A. Mader, B. Larcher, D. Zanolin-Purin, A. Leiberer, A. Muendlein, H. Drexel, Single and joint impact of type 2 diabetes and of congestive heart failure on albuminuria, J. Diabetes Complicat. 35 (12) (2021) 108046 Epub 2021 Sep 12. PMID: 34598838, doi:10.1016/j.jdiacomp.2021.108046.
[2] P. Ponikowski, A.A. Voors, S.D. Anker, et al., 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC, Eur. Heart J. 37 (27) (2016) 2129–2220, doi:10.1093/eurheartj/ehw128.
[3] H. Drexel, F.W. Amann, J. Beran, et al., Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis, Circulation 90 (5) (1994) 2230–2235, doi:10.1161/01.cir.90.5.2230.
[4] American Diabetes Association. 2, Classification and diagnosis of diabetes: standards of medical care in diabetes-2020, Diabetes Care 43 (Suppl 1) (2020) S14–S31, doi:10.2337/dc20-S002.
[5] S. Masson, R. Latini, V. Milani, et al., Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-heart failure trial. Circ. Heart Fail. 3 (1) (2010) 65–72, doi:10.1161/CIRCHEARTFAILURE.109.881805.
[6] C.E. Jackson, S.D. Solomon, H.C. Gerstein, et al., Albuminuria in chronic heart failure: prevalence and prognostic importance, Lancet 374 (9689) (2009) 543–550, doi:10.1016/S0140-6736(09)61378-7.
[7] M.K. Svensson, J. Cederholm, B. Eliasson, B. Zethelius, S. Gudbjornsdottir, Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish national diabetes register, Diabetes Vasc. Dis. Res. 10 (6) (2013) 520–529, doi:10.1177/1479164113500798.
[8] B.M. Scirica, O. Mosenzon, D.L. Bhatt, et al., Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk: observations From the SAVOR-TIMI 53 trial, JAMA Cardiol. 3 (2) (2018) 155–163, doi:10.1001/jamacardio.2017.4228.
[9] I.M. van der Meer, P. Ruggenenti, G. Remuzzi, The diabetic CKD patient – a major cardiovascular challenge, J. Ren. Care. 36 (Suppl 1) (2010) 34–46, doi:10.1111/j.1755-6686.2010.00165.x.